Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...
American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $157 from $192 and keeps an Equal Weight rating on the ...
Wedbush analyst Laura Chico lowered the firm’s price target on Biogen (BIIB) to $135 from $166 and keeps a Neutral rating on the shares. The ...
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results